Literature DB >> 12898324

The biochemical and biological functions of human papillomavirus type 16 E5 protein.

T-C Tsai1, S-L Chen.   

Abstract

Human papillomavirus type 16 (HPV-16) E5 protein, along with the more publicized E6 and E7 proteins of this virus, has been found to be oncogenic. E5 is a highly hydrophobic membrane-bound protein of 83 amino acids associated with the Golgi apparatus, endoplasmic reticulum, and nuclear membrane in infected cells. E5 can activate epidermal growth factor receptor (EGFR) through binding to the 16 kD subunit of protein pump ATPase leading to a reduced downregulation of EGFR receptors. The activation of EGFR can initiate biochemical cascades that lead to overexpression of a variety of protooncogenes and stimulate rapid cell growth. Moreover, E5 can inhibit the expression of tumor suppressor gene p21((WafI/SdiI/CipI)) and impair the control of cell cycle checkpoint. E5 protein has been identified as a potential tumor vaccine target antigen.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12898324     DOI: 10.1007/s00705-003-0111-z

Source DB:  PubMed          Journal:  Arch Virol        ISSN: 0304-8608            Impact factor:   2.574


  24 in total

1.  The human papillomavirus type 16 E5 oncoprotein inhibits epidermal growth factor trafficking independently of endosome acidification.

Authors:  Frank A Suprynowicz; Ewa Krawczyk; Jess D Hebert; Sawali R Sudarshan; Vera Simic; Christopher M Kamonjoh; Richard Schlegel
Journal:  J Virol       Date:  2010-08-04       Impact factor: 5.103

2.  Cytotoxic T-lymphocyte responses to human papillomavirus type 16 E5 and E7 proteins and HLA-A*0201-restricted T-cell peptides in cervical cancer patients.

Authors:  Dai-Wei Liu; Yuh-Cheng Yang; Ho-Fan Lin; Mei-Fang Lin; Ya-Wen Cheng; Chen-Chung Chu; Yeou-Ping Tsao; Show-Li Chen
Journal:  J Virol       Date:  2007-01-03       Impact factor: 5.103

Review 3.  Role of Zn2+ ions in host-virus interactions.

Authors:  Maciej Lazarczyk; Michel Favre
Journal:  J Virol       Date:  2008-09-10       Impact factor: 5.103

Review 4.  HPV Vaccines: today and in the Future.

Authors:  Anna-Barbara Moscicki
Journal:  J Adolesc Health       Date:  2008-10       Impact factor: 5.012

5.  Cetuximab Plus Chemoradiotherapy in Immunocompetent Patients With Anal Carcinoma: A Phase II Eastern Cooperative Oncology Group-American College of Radiology Imaging Network Cancer Research Group Trial (E3205).

Authors:  Madhur K Garg; Fengmin Zhao; Joseph A Sparano; Joel Palefsky; Richard Whittington; Edith P Mitchell; Mary F Mulcahy; Karin I Armstrong; Nassim H Nabbout; Shalom Kalnicki; Bassel F El-Rayes; Adedayo A Onitilo; Daniel J Moriarty; Thomas J Fitzgerald; Al B Benson
Journal:  J Clin Oncol       Date:  2017-01-09       Impact factor: 44.544

6.  Graphene nanoribbons elicit cell specific uptake and delivery via activation of epidermal growth factor receptor enhanced by human papillomavirus E5 protein.

Authors:  Sayan Mullick Chowdhury; Prady Manepalli; Balaji Sitharaman
Journal:  Acta Biomater       Date:  2014-06-27       Impact factor: 8.947

Review 7.  Human Immunodeficiency Virus/AIDS, Human Papillomavirus, and Anal Cancer.

Authors:  Chia-Ching J Wang; Joseph Sparano; Joel M Palefsky
Journal:  Surg Oncol Clin N Am       Date:  2017-01       Impact factor: 3.495

Review 8.  Human papillomavirus type 16 E5 protein as a therapeutic target.

Authors:  Sang-Woo Kim; Joo-Sung Yang
Journal:  Yonsei Med J       Date:  2006-02-28       Impact factor: 2.759

9.  High-risk HPV E5-induced cell fusion: a critical initiating event in the early stage of HPV-associated cervical cancer.

Authors:  Peng Gao; Jie Zheng
Journal:  Virol J       Date:  2010-09-16       Impact factor: 4.099

10.  Cytotoxic-T-lymphocyte human papillomavirus type 16 E5 peptide with CpG-oligodeoxynucleotide can eliminate tumor growth in C57BL/6 mice.

Authors:  Yi-Fang Chen; Chih-Wei Lin; Yeou-Ping Tsao; Show-Li Chen
Journal:  J Virol       Date:  2004-02       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.